This article needs more reliable medical references for verification or relies too heavily on primary sources. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed. Find sources: "XW10508" – news · newspapers · books · scholar · JSTOR (November 2024) |
Clinical data | |
---|---|
Other names | XW10508; XW-10508 |
Routes of administration | Oral[1][2][3] |
Drug class | NMDA receptor antagonist; Antidepressant; Analgesic; Dissociative; Hallucinogen |
XW10508 is an orally active prodrug of esketamine, an NMDA receptor antagonist, which is under development for the treatment of major depressive disorder and chronic pain.[1][4][2][3] It is taken by mouth.[1][2][3]
The drug is a novel esketamine analogue and conjugate that acts as a prodrug of esketamine.[3] Esketamine, and by extension XW10508, is an NMDA receptor antagonist and indirect AMPA receptor activator.[1][5] XW10508 is being developed as once-daily orally administered extended-release and immediate-release formulations with misuse resistance.[1][3]
As of August 2024, XW10508 is in phase 2 clinical trials for major depressive disorder and is in phase 1 clinical trials for chronic pain.[1][4][2] However, no recent development has been reported for these indications.[1] The drug is being developed by XWPharma, which was previously known as XW Laboratories.[1][4][2] It is being developed in Australia.[1][2] The chemical structure of XW10508 does not yet seem to have been disclosed.[1]
References
[edit]- ^ a b c d e f g h i j "XW 10508". AdisInsight. 28 August 2024. Retrieved 2 November 2024.
- ^ a b c d e f "XW-10508 Drug Profile". Ozmosi. 13 April 2024. Retrieved 2 November 2024.
XW10508 is an internally discovered, investigational, orally bioavailable, once-daily glutamatergic providing NMDA receptor inhibition and AMPA receptor activation in development for the intended treatment of MDD and chronic pain.
- ^ a b c d e "XWPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic Pain". GlobeNewswire News Room (Press release). 8 September 2021. Retrieved 2 November 2024.
- ^ a b c "Delving into the Latest Updates on XW-10508 with Synapse". Synapse. 1 November 2024. Retrieved 2 November 2024.
- ^ Jelen LA, Young AH, Stone JM (February 2021). "Ketamine: A tale of two enantiomers". J Psychopharmacol. 35 (2): 109–123. doi:10.1177/0269881120959644. PMC 7859674. PMID 33155503.
External links
[edit]AMPARTooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor |
|
---|---|
KARTooltip Kainate receptor |
|
NMDARTooltip N-Methyl-D-aspartate receptor |
|
- Articles with short description
- Short description with empty Wikidata description
- Articles needing additional medical references from November 2024
- All articles needing additional references
- Articles requiring reliable medical sources
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes